Miles Miller has been admitted to the Bridging Academia with Industry Training Program at Mass General Research Institute designed to foster collaborations between academia and industry and support a new generation of translationally-minded scientists.
CSB has been named as one of the NCI Innovative Research in Cancer Nanotechnology (IRCNs). The IRCNs engage in directed, product-focused research that aims to translate cutting-edge science and technology into the next generation of diagnostic and therapeutic tools. These platforms serve as the core technologies for a wide array of specific applications that will ultimately benefit cancer patients.
Miles Miller, PhD and Kevin King, MD, PhD have been selected to serve as Associate Scientific Advisors (ASAs) for Science's sister journal, Science Translational Medicine, for 2017-2018.